Chemicals · Founded 1989 · www.resonancesl.com · BSE 524218 · · ISIN INE486D01017
No Notes Added Yet
Business
Resonance Specialties Ltd. is an Indian specialty chemicals manufacturer. The company primarily focuses on the production of Piperazine and its derivatives, along with various polymer additives and other tailor-made specialty chemicals. Its core business model is B2B (Business-to-Business), supplying these chemical intermediates and additives to a diverse range of industries including pharmaceuticals, agrochemicals, plastics, textiles, and other industrial applications. The company makes money by manufacturing and selling these specialized chemical products, leveraging its technical expertise and manufacturing capabilities.
Revenue Mix
While a granular segment breakdown with specific revenue percentages is not always publicly detailed for all Indian specialty chemical companies, Resonance Specialties primarily operates across the following product categories:
Piperazine and its Derivatives: A significant focus, catering to pharmaceutical, agrochemical, and other specialty chemical industries.
Polymer Additives: Such as antioxidants and UV stabilizers, essential for the plastics and polymer industries.
Other Specialty Chemicals: Often custom-synthesized products for specific industrial requirements.
The revenue is derived from the sales of these manufactured products to industrial clients.
Industry
Resonance Specialties operates within the broad Indian Chemicals sector, specifically the Specialty Chemicals industry. This industry is characterized by high growth potential, driven by domestic demand and export opportunities, and typically involves specialized manufacturing processes and application-specific products. Resonance is positioned as a niche player, particularly known for its expertise in Piperazine chemistry. It competes with both domestic and international specialty chemical manufacturers. Its positioning relies on product quality, adherence to specific customer requirements, and technical know-how in its chosen product areas, rather than broad commodity chemical production.
MOAT
Resonance Specialties' competitive advantages likely stem from:
Niche Expertise & Product Specialization: Deep technical knowledge and experience in manufacturing complex chemicals like Piperazine derivatives create entry barriers for new competitors. This allows them to cater to specific, high-value applications.
Customer Relationships & Switching Costs: For specialty chemicals, customers often require specific grades and quality, leading to long-term relationships and higher switching costs once a supplier is approved and integrated into their supply chain.
Process Know-how: Proprietary manufacturing processes or optimized production methods can lead to cost efficiencies and consistent product quality, differentiating them from competitors.
Growth Drivers
Growing End-User Industries: Increased demand from key client sectors like pharmaceuticals, agrochemicals, and plastics drives the need for specialty chemical intermediates and additives.
Rising Demand for Specialty Chemicals: Global shift towards higher-value, application-specific specialty chemicals, moving away from commoditized bulk chemicals.
Capacity Expansion: Any planned or ongoing expansion projects to meet growing demand and diversify product offerings.
Product Diversification & Innovation: Development of new products or grades to capture emerging market opportunities and serve new applications.
Export Market Growth: Leveraging India's competitive manufacturing costs and global supply chain realignments to increase export penetration.
Risks
Raw Material Price Volatility: Dependence on crude oil derivatives or other commodity chemicals as inputs makes the company susceptible to price fluctuations, impacting profitability.
Intense Competition: Competition from both domestic and international players can lead to pricing pressures and margin erosion.
Regulatory & Environmental Changes: Strict environmental norms, safety regulations, and other government policies can increase operational costs, require significant capital expenditure for compliance, or affect production.
Technological Obsolescence: The need for continuous R&D and process upgrades to remain competitive in a rapidly evolving chemical landscape.
Foreign Exchange Fluctuations: Exposure to currency risks due to import of raw materials or export of finished products.
Management & Ownership
Resonance Specialties Ltd. is a promoter-driven company, which is common in India. The promoter group typically holds a significant stake, indicating a long-term commitment to the business. Management quality can be assessed by their strategic decisions, focus on R&D, capacity expansion plans, and corporate governance practices. The promoter holding provides stability but also means decisions are often concentrated.
Outlook
Resonance Specialties operates in the resilient and growing Indian specialty chemicals sector, benefiting from a diversified end-user base (pharma, agro, plastics). Its niche focus on products like Piperazine derivatives provides a degree of insulation from broader commodity cycles and fosters strong customer relationships, which can be a source of stable revenue. However, the company faces inherent risks associated with the chemical industry, including the volatility of raw material prices, intense competition, and stringent environmental regulations that necessitate continuous investment in compliance and R&D. Future growth will be contingent on successfully navigating these challenges, executing planned capacity expansions, diversifying its product portfolio, and capitalizing on the structural growth drivers of its key end-user industries both domestically and internationally.
| #(Fig in Cr.) | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Net Sales | 16 | 17 | 18 | 18 | 24 | 21 | 22 | 23 | 24 | 33 |
| Other Income | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 |
| Total Income | 17 | 18 | 18 | 19 | 24 | 22 | 22 | 23 | 25 | 33 |
| Total Expenditure | 15 | 15 | 16 | 16 | 20 | 19 | 19 | 20 | 19 | 25 |
| Operating Profit | 1 | 2 | 3 | 2 | 4 | 3 | 3 | 4 | 6 | 8 |
| Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Depreciation | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Exceptional Income / Expenses | 0 | -1 | 0 | 0 | -0 | 0 | 0 | 0 | 0 | 0 |
| Profit Before Tax | 1 | 1 | 2 | 2 | 4 | 2 | 2 | 3 | 6 | 8 |
| Provision for Tax | 0 | 0 | 0 | 1 | 1 | 1 | 1 | 1 | 1 | 2 |
| Profit After Tax | 1 | 1 | 2 | 1 | 3 | 2 | 2 | 3 | 5 | 6 |
| Adjustments | -0 | -0 | -0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Profit After Adjustments | 1 | 1 | 2 | 1 | 3 | 2 | 2 | 3 | 5 | 6 |
| Adjusted Earnings Per Share | 0.6 | 0.5 | 1.6 | 1 | 2.6 | 1.4 | 1.4 | 2.2 | 4 | 5 |
| #(Fig in Cr.) | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Sales | 39 | 34 | 36 | 40 | 56 | 70 | 76 | 59 | 55 | 78 | 90 | 102 |
| Other Income | 0 | 1 | 1 | 1 | 2 | 2 | 1 | 2 | 1 | 1 | 2 | 2 |
| Total Income | 39 | 35 | 37 | 42 | 58 | 72 | 77 | 60 | 56 | 79 | 92 | 103 |
| Total Expenditure | 36 | 32 | 35 | 35 | 48 | 56 | 59 | 52 | 50 | 67 | 76 | 83 |
| Operating Profit | 3 | 3 | 2 | 6 | 10 | 16 | 18 | 8 | 6 | 12 | 16 | 21 |
| Interest | 1 | 0 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Depreciation | 1 | 1 | 1 | 1 | 1 | 1 | 2 | 1 | 1 | 2 | 1 | 0 |
| Exceptional Income / Expenses | 0 | 0 | -0 | -0 | -1 | 0 | 0 | 0 | 0 | -1 | 0 | 0 |
| Profit Before Tax | 2 | 1 | 0 | 5 | 7 | 15 | 16 | 7 | 4 | 9 | 14 | 19 |
| Provision for Tax | 0 | 0 | 1 | 2 | 1 | 4 | 4 | 2 | 1 | 2 | 4 | 5 |
| Profit After Tax | 1 | 1 | -1 | 3 | 6 | 11 | 12 | 5 | 3 | 7 | 10 | 16 |
| Adjustments | 0 | 0 | 0 | -0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Profit After Adjustments | 1 | 1 | -1 | 3 | 6 | 11 | 12 | 5 | 3 | 7 | 10 | 16 |
| Adjusted Earnings Per Share | 1 | 0.9 | -0.6 | 2.8 | 4.8 | 9.1 | 10.7 | 4.3 | 2.6 | 5.7 | 9 | 12.6 |
| # | 1 Year | 3 Year | 5 Year | 10 Year |
|---|---|---|---|---|
| Sales CAGR | 15% | 15% | 5% | 9% |
| Operating Profit CAGR | 33% | 26% | 0% | 18% |
| PAT CAGR | 43% | 26% | -2% | 26% |
| # | 1 Year | 3 Year | 5 Year | 10 Year |
|---|---|---|---|---|
| Share Price CAGR | 107% | 28% | -2% | 16% |
| ROE Average | 16% | 11% | 15% | 14% |
| ROCE Average | 21% | 15% | 20% | 21% |
| #(Fig in Cr.) | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Shareholder's Funds | 23 | 24 | 23 | 26 | 31 | 41 | 52 | 56 | 57 | 64 | 73 |
| Minority's Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Borrowings | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2 | 3 | 2 | 1 |
| Other Non-Current Liabilities | 1 | 1 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 |
| Total Current Liabilities | 8 | 15 | 12 | 10 | 9 | 12 | 3 | 7 | 11 | 8 | 16 |
| Total Liabilities | 32 | 40 | 37 | 38 | 41 | 55 | 57 | 66 | 74 | 76 | 92 |
| Fixed Assets | 14 | 15 | 15 | 14 | 14 | 16 | 14 | 20 | 23 | 21 | 21 |
| Other Non-Current Assets | 1 | 2 | 2 | 2 | 3 | 1 | 1 | 1 | 1 | 2 | 5 |
| Total Current Assets | 17 | 23 | 20 | 22 | 24 | 38 | 42 | 45 | 50 | 52 | 67 |
| Total Assets | 32 | 40 | 37 | 38 | 41 | 55 | 57 | 66 | 74 | 76 | 92 |
| #(Fig in Cr.) | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Opening Cash & Cash Equivalents | 1 | 1 | 1 | 1 | 2 | 2 | 6 | 9 | 4 | 0 | 0 |
| Cash Flow from Operating Activities | 3 | 1 | 2 | 5 | 1 | 4 | 13 | -8 | 4 | -3 | 17 |
| Cash Flow from Investing Activities | -1 | -3 | -1 | -1 | -2 | -1 | -9 | 3 | -7 | 4 | -15 |
| Cash Flow from Financing Activities | -2 | 2 | -1 | -4 | 1 | 0 | -2 | 1 | 0 | -1 | -2 |
| Net Cash Inflow / Outflow | 0 | -0 | 0 | 1 | 1 | 3 | 3 | -4 | -2 | -0 | -0 |
| Closing Cash & Cash Equivalent | 1 | 1 | 1 | 2 | 2 | 6 | 9 | 4 | 2 | 0 | 0 |
| # | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Per Share (Rs) | 1.03 | 0.89 | -0.6 | 2.78 | 4.77 | 9.12 | 10.71 | 4.33 | 2.57 | 5.69 | 9.01 |
| CEPS(Rs) | 2 | 1.81 | 0.39 | 3.56 | 5.57 | 9.97 | 12.22 | 5.61 | 3.83 | 7.04 | 10.16 |
| DPS(Rs) | 0 | 0 | 0 | 0 | 1 | 1 | 1 | 1 | 0 | 1 | 1 |
| Book NAV/Share(Rs) | 14.77 | 15.88 | 15.27 | 18.05 | 21.57 | 30.35 | 40 | 43.37 | 46.63 | 52.28 | 60.27 |
| Core EBITDA Margin(%) | 7.29 | 5.41 | 1.66 | 10.62 | 12.17 | 18.31 | 19.7 | 10.36 | 8.71 | 13.7 | 15.61 |
| EBIT Margin(%) | 5.21 | 4.81 | 1.76 | 11.65 | 11.41 | 19.08 | 19.23 | 10.57 | 7.76 | 11.94 | 15.95 |
| Pre Tax Margin(%) | 3.96 | 3.75 | 0.34 | 10.47 | 10.86 | 18.7 | 19.15 | 10.41 | 7.17 | 11.41 | 15.59 |
| PAT Margin (%) | 2.88 | 2.77 | -1.79 | 7.05 | 8.64 | 13.52 | 14.54 | 7.6 | 5.37 | 8.44 | 11.52 |
| Cash Profit Margin (%) | 5.57 | 5.63 | 1.16 | 9.05 | 10.08 | 14.78 | 16.59 | 9.84 | 8 | 10.44 | 13 |
| ROA(%) | 3.56 | 2.85 | -1.81 | 8.54 | 13.89 | 21.98 | 22.19 | 8.16 | 4.25 | 8.79 | 12.37 |
| ROE(%) | 7.24 | 5.8 | -3.86 | 16.66 | 24.08 | 35.11 | 30.44 | 10.39 | 5.71 | 11.5 | 16 |
| ROCE(%) | 11.37 | 8.62 | 3.14 | 25.29 | 31.51 | 48.33 | 39.75 | 14.14 | 7.79 | 15.31 | 21.31 |
| Receivable days | 76.13 | 70.95 | 66.07 | 57.12 | 39.24 | 36.46 | 37.82 | 56.93 | 84.68 | 83.71 | 73.33 |
| Inventory Days | 68.54 | 106.26 | 110.4 | 75.54 | 63.74 | 70.23 | 60.6 | 96.41 | 151.64 | 115.05 | 122.4 |
| Payable days | 119.03 | 199.93 | 165.24 | 130.07 | 116.55 | 107.26 | 72.52 | 84.83 | 103.79 | 86.84 | 81.7 |
| PER(x) | 19.28 | 45.44 | 0 | 7.31 | 5.29 | 13.76 | 16.47 | 17.9 | 35.08 | 11.79 | 8.65 |
| Price/Book(x) | 1.35 | 2.54 | 1.85 | 1.12 | 1.17 | 4.13 | 4.41 | 1.79 | 1.93 | 1.28 | 1.29 |
| Dividend Yield(%) | 0 | 0 | 0 | 0 | 3.96 | 0.8 | 0.57 | 1.29 | 0 | 1.49 | 1.28 |
| EV/Net Sales(x) | 0.62 | 1.47 | 0.99 | 0.54 | 0.48 | 1.99 | 2.57 | 1.49 | 1.92 | 1.03 | 1.01 |
| EV/Core EBITDA(x) | 7.34 | 17.64 | 19.14 | 3.5 | 2.81 | 8.84 | 10.78 | 10.37 | 18.46 | 6.86 | 5.81 |
| Net Sales Growth(%) | 2.4 | -12.16 | 5.2 | 11.96 | 39.43 | 25.21 | 7.78 | -22.36 | -5.97 | 40.7 | 15.99 |
| EBIT Growth(%) | 10.15 | -17.39 | -61.75 | 676.45 | 37.42 | 104.19 | 10.1 | -57.46 | -38.34 | 116.54 | 54.9 |
| PAT Growth(%) | -6.63 | -13.83 | -167.63 | 561.68 | 71.86 | 91.08 | 17.44 | -59.54 | -40.65 | 121.2 | 58.32 |
| EPS Growth(%) | -6.63 | -13.84 | -167.63 | 561.68 | 71.86 | 91.08 | 17.44 | -59.54 | -40.65 | 121.2 | 58.32 |
| Debt/Equity(x) | 0.11 | 0.22 | 0.19 | 0 | 0.02 | 0.03 | 0 | 0.04 | 0.08 | 0.05 | 0.03 |
| Current Ratio(x) | 2.03 | 1.58 | 1.71 | 2.28 | 2.78 | 3.12 | 12.52 | 6.7 | 4.32 | 6.76 | 4.12 |
| Quick Ratio(x) | 1.08 | 0.65 | 0.87 | 1.35 | 1.21 | 1.75 | 9.02 | 3.23 | 2.33 | 3.36 | 2.01 |
| Interest Cover(x) | 4.16 | 4.52 | 1.24 | 9.88 | 20.53 | 51.15 | 238.42 | 65.09 | 13.11 | 22.49 | 45.09 |
| Total Debt/Mcap(x) | 0.08 | 0.09 | 0.1 | 0 | 0.02 | 0.01 | 0 | 0.02 | 0.04 | 0.04 | 0.02 |
| # | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Promoter | 54.25 | 54.25 | 54.25 | 54.25 | 54.25 | 54.25 | 54.25 | 54.25 | 54.25 | 54.25 |
| FII | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| DII | 0.03 | 0.03 | 0.03 | 0.03 | 0.03 | 0.03 | 0.03 | 0.03 | 1.55 | 1.55 |
| Public | 45.72 | 45.72 | 45.72 | 45.72 | 45.72 | 45.72 | 45.72 | 45.72 | 44.2 | 44.2 |
| Others | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 |
| # | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Promoter | 0.63 | 0.63 | 0.63 | 0.63 | 0.63 | 0.63 | 0.63 | 0.63 | 0.63 | 0.63 |
| FII | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| DII | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0.02 | 0.02 |
| Public | 0.53 | 0.53 | 0.53 | 0.53 | 0.53 | 0.53 | 0.53 | 0.53 | 0.51 | 0.51 |
| Others | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 1.15 | 1.15 | 1.15 | 1.15 | 1.15 | 1.15 | 1.15 | 1.15 | 1.15 | 1.15 |
| # | 1 Year | 3 Year | 5 Year | 10 Year |
|---|---|---|---|---|
| Sales CAGR | +15% | +15% | +5% | +9% |
| Operating Profit CAGR | +33% | +26% | 0% | +18% |
| PAT CAGR | +43% | +26% | -2% | +26% |
| Share Price CAGR | +107% | +28% | -2% | +16% |
| ROE Average | +16% | +11% | +15% | +14% |
| ROCE Average | +21% | +15% | +20% | +21% |
| # | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Promoter | 54.25 | 54.25 | 54.25 | 54.25 | 54.25 | 54.25 | 54.25 | 54.25 | 54.25 | 54.25 |
| FII | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| DII | 0.03 | 0.03 | 0.03 | 0.03 | 0.03 | 0.03 | 0.03 | 0.03 | 1.55 | 1.55 |
| Public | 45.72 | 45.72 | 45.72 | 45.72 | 45.72 | 45.72 | 45.72 | 45.72 | 44.2 | 44.2 |
| Others | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 |
| # | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Promoter | 0.63 | 0.63 | 0.63 | 0.63 | 0.63 | 0.63 | 0.63 | 0.63 | 0.63 | 0.63 |
| FII | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| DII | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0.02 | 0.02 |
| Public | 0.53 | 0.53 | 0.53 | 0.53 | 0.53 | 0.53 | 0.53 | 0.53 | 0.51 | 0.51 |
| Others | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 1.15 | 1.15 | 1.15 | 1.15 | 1.15 | 1.15 | 1.15 | 1.15 | 1.15 | 1.15 |
* The pros and cons are machine generated.
Our experts help you choose the right stocks based on performance, risk, and growth potential.
Looking to buy unlisted shares or need guidance on the investment process? Our expert Private Equity Advisors are here to assist you with accurate information, real-time pricing, and seamless execution.
Want to sell unlisted shares, liquidate your ESOPs, or understand the step-by-step process of liquidation? Connect with our Buying Team for smooth coordination, quick evaluations, and end-to-end support.
Planning to build or grow your portfolio? For Mutual Fund investments, PMS solutions, tailored portfolio creation, and overall wealth management, our dedicated Wealth Team is ready to guide you.
Your relationship manager will connect with you shortly.